Opinion editor’s note: Editorials represent the opinions of the Star Tribune Editorial Board, which operates independently from the newsroom.
•••
It began with a teacup and saucer at a work event. It was 2010, and Sherrie Pugh picked up the offending objects, but, before she could get coffee, the uncontrollable rattling prompted a helpful staffer to intervene. A function Pugh thought she’d have for life, that of pouring coffee: gone. It would take five years of tremors, and countless doctor visits in that time, before Pugh, now 73, would receive a Parkinson’s diagnosis.
The case of Pugh’s is hardly out of the ordinary. Parkinson’s disease, despite its potentially debilitating nature, is notoriously difficult to diagnose, with many patients suffering for years before receiving proper diagnosis and treatment.
So the optimism with which the National Plan to End Parkinson’s Act, signed into law by President Joe Biden on July 2, has been received nationwide, is understandable. This is a welcome development for the Parkinson’s community and long overdue. The legislation directs the U.S. Department of Health and Human Services to develop a national plan to better diagnose and treat the disease, as well as prevent it. In addition, it establishes an advisory council to assist federal officials. The bill’s passage also puts a helpful spotlight on the disorder, yielding greater awareness of Parkinson’s and encouragement for patients like Pugh, who lives in Mound.
This act was modeled off the 2011 National Alzheimer’s Project Act, which laid the groundwork for public investments of over $3.8 billion in federal revenue to combat Alzheimer’s. While it’s a shame that it has taken over a decade for the government to make a similar commitment to fighting Parkinson’s (which received $259 million in research funding from the NIH in 2022), hopefully the same investment and attention that followed the Alzheimer’s bill will be devoted to Parkinson’s in the wake of this new bill.
The bill, backed by strong bipartisan support, calls for improved treatments and cures, furthering federal support for research and promoting preventive measures. The targeted approach has the potential to change the way millions experience this debilitating neurodegenerative disease, whose symptoms include tremors, mobility problems and cognitive decline.
Currently, over 1 million Americans suffer nationwide, with 20,000 Minnesotans currently afflicted. The disease’s total economic burden is $52 billion nationwide annually, according to 2023 data. Patients can also face thousands in medical bills for care.